MedTrace Logo

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

NCT02347176 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2018-05-23

Study results available
· View outcomes & findings →

Summary

The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis

Conditions

Interventions

OTHER

Placebo

Subcutaneous injection with placebo

BIOLOGICAL

Tralokinumab Dose 1

Subcutaneous injection with tralokinumab

BIOLOGICAL

Tralokinumab Dose 2

Subcutaneous injection with tralokinumab

BIOLOGICAL

Tralokinumab Dose 3

Subcutaneous injection with tralokinumab

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-23
Primary Completion
2015-11-27
Completion
2016-02-05

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Japan
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02347176 on ClinicalTrials.gov